Key result
Dual antiplatelet therapy reduces non-fatal MI ~32%, though residual ischemic and bleeding risks persist.
While current antiplatelet therapies significantly reduce ischemic events, their limitations regarding residual risk and bleeding underscore the need for personalized pharmacological strategies.
Answers are grounded in this paper and cite their sources.
Cautions against uniform antiplatelet regimens due to bleeding; leaves open personalized strategies to address residual risk.
Platelets play a central role in the pathophysiology of atherothrombosis, an inappropriate platelet activation leading to acute ischemic complications (acute myocardial infarction, ischemic stroke). In view of this, platelets are a major target for pharmacotherapy. Presently, the main classes of antiplatelet agents approved for the use in such complications are aspirin and thienopyridines. Although antiplatelet treatment with these two types of drugs, alone or in combination, leads to a significant reduction of non-fatal myocardial infarction (-32%), non-fatal stroke (-25%), and of cardiovascular death (-17%), a residual risk persists. Newer antiplatelet agents have addressed some, but not all, these limitations. Vis-à-vis their net clinical benefit, the higher potency of some of them is associated with a rise in bleeding complications. Moreover, newer thienopyridines do not show advantages over and above the older ones as to reduction of stroke. A concerted effort that takes into consideration clinical, genetic, and laboratory information is increasingly recognized as a major direction to be pursued in the area. The well-established road signs of clinical epidemiology will provide major information to define newer potentially useful targets for platelet pharmacology.
No takes yet. Share an insight, caveat, or question.
Minno et al. (2011) conducted a review in Atherothrombosis (acute coronary syndrome, acute myocardial infarction, ischemic stroke). Antiplatelet drugs (aspirin, thienopyridines, P2Y12 inhibitors, PAR-1 antagonists) vs. Placebo or standard antiplatelet therapy (aspirin/clopidogrel) was evaluated on Major adverse cardiovascular events (non-fatal myocardial infarction, non-fatal stroke, cardiovascular death). Antiplatelet therapy with aspirin and thienopyridines reduces non-fatal MI by 32%, non-fatal stroke by 25%, and CV death by 17%, though residual risk and bleeding complications persist.
Synapse has enriched 10 related papers. Consider them for comparative context: